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Abstract
Background: Data from observational studies suggest that minimally invasive pancreatoduodenectomy (MIPD) is
superior to open pancreatoduodenectomy regarding intraoperative blood loss, postoperative morbidity, and length of
hospital stay, without increasing total costs. However, several case-matched studies failed to demonstrate superiority of
MIPD, and large registry studies from the USA even suggested increased mortality for MIPDs performed in low-volume
(<10 MIPDs annually) centers. Randomized controlled multicenter trials are lacking but clearly required. We hypothesize
that time to functional recovery is shorter after MIPD compared with open pancreatoduodenectomy, even in an
enhanced recovery setting.
Methods/design: LEOPARD-2 is a randomized controlled, parallel-group, patient-blinded, multicenter, phase 2/3,
superiority trial in centers that completed the Dutch Pancreatic Cancer Group LAELAPS-2 training program for
laparoscopic pancreatoduodenectomy or LAELAPS-3 training program for robot-assisted pancreatoduodenectomy
and have performed≥ 20 MIPDs. A total of 136 patients with symptomatic benign, premalignant, or malignant disease
will be randomly assigned to undergo minimally invasive or open pancreatoduodenectomy in an enhanced recovery
setting. After the first 40 patients (phase 2), the data safety monitoring board will assess safety outcomes (not blinded
for treatment allocation) and decide on continuation to phase 3. Patients from phase 2 will then be included in phase
3. The primary outcome measure is time (days) to functional recovery. All patients will be blinded for the surgical
approach, at least until postoperative day 5, but preferably until functional recovery has been attained. Secondary
outcome measures are operative and postoperative outcomes, including clinically relevant complications, mortality,
quality of life, and costs.
Discussion: The LEOPARD-2 trial is designed to assess whether MIPD reduces time to functional recovery, as compared
with open pancreatoduodenectomy in an enhanced recovery setting.
Trial registration: Netherlands Trial Register, NTR5689. Registered on 2 March 2016.
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Background
Pancreatoduodenectomy is the only potential curative treat-
ment option for periampullary cancer and premalignant
tumors. In 1994, minimally invasive pancreatoduodenect-
omy (MIPD) was introduced [1]. After a slow introduction,
the use of MIPD has increased rapidly in recent years.
Several cohort studies have suggested that MIPD is safe
and feasible when performed by experienced surgeons in
high-volume centers [2, 3]. However, the benefits of MIPD
in real-life clinical practice remain unclear. On the one
hand, meta-analysis of cohort studies showed that MIPD is
associated with decreased intraoperative blood loss
(weighted mean difference, −384 mL; P < 0.01), less delayed
gastric emptying (odds ratio, 0.7; P < 0.01) and decreased
length of hospital stay (weighted mean difference, −3 days;
P < 0.01) compared with open pancreatoduodenectomy. On
the other hand, MIPD increases operative time significantly
and registry studies have expressed concerns on its safety
[4]. Compared with open pancreatoduodenectomy, mortal-
ity might be doubled after MIPD in low-volume centers
performing fewer than 10 MIPD procedures annually (8%
versus 3%; P < 0.01) [4]. These studies raise concerns about
the feasibility and generalizability of MIPD and clearly dem-
onstrate the need for a randomized controlled trial, espe-
cially in this era when minimally invasive pancreatic
surgery is gaining popularity worldwide [2, 5].
The cost-effectiveness and quality of life associated
with MIPD have currently only been reported in
small observational studies [6]. These studies reported
higher operative costs of MIPD, which were compen-
sated by lower postoperative costs because of shorter
hospital stay [3]. However, the limited sample sizes of
these studies do not allow reliable conclusions. More-
over, outcomes of open pancreatoduodenectomy have
also improved in recent years with enhanced recovery
strategies leading to shorter postoperative hospital
stay [7]. These parameters should therefore be
assessed in a multicenter randomized trial using an
enhanced recovery setting for both MIPD and open
pancreatoduodenectomy.
In the Netherlands, a platform for such a multicenter
randomized trial has been created by the Dutch Pancreatic
Cancer Group (DPCG), a nationwide multidisciplinary
group including all 17 centers performing pancreatic sur-
gery in the Netherlands. The DPCG followed the inter-
nationally accepted Idea, Development, Exploration,
Assessment, and Long-term (IDEAL) study framework for
surgical innovation for the implementation of minimally
invasive pancreatic surgery in the Netherlands [8–10].
Since 2014, the DPCG successfully implemented minim-
ally invasive distal pancreatectomy in all Dutch pancreatic
centers within the LAELAPS (longitudinal assessment and
realization of laparoscopic pancreatic surgery) project
[11]. Thereafter, the DPCG initiated a similar nationwide
training program for laparoscopic pancreatoduodenect-
omy (the LAELAPS-2 project) [12]. This program in-
cluded detailed technique description, video training, and
proctoring sessions (on-site and off-site) by (inter)national
experts. Analysis of outcomes of 114 MIPDs performed
within LAELAPS-2, in the first four DPCG centers that
performed >20 MIPDs, showed an 11% conversion rate, a
43% Clavien–Dindo III or higher complication rate, and a
4% complication-related 90-day mortality [12]. Hereafter,
a structured training program in robot-assisted pancreato-
duodenectomy using the Pittsburgh approach (the
LAELAPS-3 project) was implemented [13]. Based on
these outcomes and the IDEAL study framework [8–10],
it was decided that a randomized controlled trial was indi-
cated in those centers that performed at least 20 MIPDs.
The LEOPARD-2 trial follows the LEOPARD trial on
minimally invasive versus open distal pancreatectomy [14]
but has a phase 2/3 design to assess patient safety more
closely. The aim of the LEOPARD-2 trial is to compare
time to functional recovery after surgery, complications,
quality of life, and costs after MIPD versus open pancrea-
toduodenectomy, within an enhanced recovery setting.
Methods
Design
The LEOPARD-2 trial is a randomized controlled, parallel-
group, patient-blinded, multicenter, phase 2/3, superiority
trial investigating the safety and effectiveness of MIPD
versus open pancreatoduodenectomy, in an enhanced
recovery setting at high-volume (≥20 pancreatoduodenec-
tomies annually) pancreatic centers who completed a dedi-
cated MIPD training program. Eligible patients will be
randomized in a 1:1 ratio to either minimally invasive or
open pancreatoduodenectomy.
Trial population
All adult patients with an indication for elective pancreato-
duodenectomy because of malignant, premalignant, or
symptomatic benign disease in the pancreatic and periam-
pullary region will be screened for eligibility.
Inclusion criteria
Inclusion criteria are as follows:
 Age at least 18 years
 Indication for elective pancreatoduodenectomy
 Both minimally invasive and open
pancreatoduodenectomy feasible, according to the
surgical team (based on computed tomography
performed a maximum of 4 weeks before surgery)
 Fit to undergo pancreatoduodenectomy, according
to the surgical and anesthesiological team
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Exclusion criteria
Exclusion criteria are as follows:
 Tumor involvement of portal vein, superior
mesenteric vein, superior mesenteric artery, or
hepatic artery (based on computed tomography
performed a maximum of 4 weeks before surgery)
 Body mass index > 35 kg/m2
 Neo-adjuvant pancreatic radiotherapy
 Second cancer requiring resection during the same
procedure
 Pregnancy
 Participation in another study with interference of
study outcomes
Randomization
Eligible patients will be recruited at the outpatient clinic.
Written informed consent must be provided before inclu-
sion. Included patients will be randomized centrally by the
study coordinators (TdR and JvH) using an online
randomization module (ALEA, Clinical Research Unit,
Academic Medical Center, Amsterdam, the Netherlands) in
a 1:1 ratio between MIPD and open pancreatoduodenect-
omy (Fig. 1). Randomization will be stratified by center to
balance differences in surgical procedure and general treat-
ment regimen and by the preoperative probability of devel-
oping a postoperative pancreatic fistula: high risk (i.e.
pancreatic duct diameter < 3 mm or body mass index >
25 kg/m2) versus low risk (i.e. i.e. pancreatic duct diam-
eter ≥ 3 mm and body mass index ≤ 25 kg/m2). Stratifica-
tion based on intraoperative patient characteristics was
considered impossible. Permuted-block randomization will
be used to provide treatment allocation in equal propor-
tions, with block sizes ranging from 2 to 6, subject to ran-
dom variation. This will be concealed to all investigators
involved in the trial.
Intervention: minimally invasive pancreatoduodenectomy
Here we describe the standard operative technique. Small
variations according to the surgeon’s preference, such as a
different order of steps or pancreatic anastomosis
technique, are allowed, but must be recorded in the case
record form. Both laparoscopic surgery and robot-assisted
surgery, e.g. using the da Vinci® Surgical System, are
allowed as both are considered equivalent methods of
MIPD.
All procedures are performed by two trained gastrointes-
tinal surgeons (see section on quality and safety). Patients
are under general anesthesia; epidural is not mandatory.
The patient is placed in a supine position on a bean bag.
The right arm is placed along the body and the left arm in
90° abduction. The suprapubic region is kept free for a
Pfannenstiel incision. Trocars are placed in a soft semicir-
cular fashion: subumbilical (12 mm trocar), left and right to
the umbilicus (two 12 mm trocars), 4 cm subcostal (two
5 mm trocars), with an optional 5 mm subxiphoïdal trocar
for liver retraction. Diagnostic laparoscopy is performed to
rule out metastasis. The cystic duct and artery are trans-
ected, the gallbladder is partly mobilized and sutured to the
anterior abdominal wall for liver retraction. Likewise, the
round ligament is retracted to the anterior abdominal wall,
with either a suture or retractor. The lesser sac is opened
and a Kocher maneuver is performed. The inferior border
of the pancreas and the superior mesenteric vein are visual-
ized. The gastro-epiploic artery and vein are transected.
Lymph node station 8a is dissected, followed by identifica-
tion of the hepatic artery, gastroduodenal artery, and portal
vein. The gastroduodenal artery is transected between mul-
tiple Hem-o-lok clips (Teleflex Medical, Research Triangle
Park, NC, USA). A tunnel is created under the pancreas
and a 15 cm long vessel loop is passed and secured to itself.
The stomach is transected just proximal or distal to the
pylorus using an endostapler after temporary removal of
the nasogastric tube. The pancreas is transected using
diathermia or an ultrasonic or sealing device, but the
pancreatic duct is transected sharply with scissors and
intubated to ensure that it is open. The first jejunal limb is
dissected from the peritoneal reflections, transected using
an endostapler, and fully mobilized. The two jejunal ends
are fixated using a suture, thus facilitating passing behind
the mesenteric root. After retracting the duodenum and
jejunum to the right side of the mesenteric root, the
duodenum is stretched and the uncinate process is
mobilized. First, the superior mesenteric vein and then the
superior mesenteric artery branches are mobilized until the
pancreatic head is fully dissected. The common hepatic
artery is followed up to the right hepatic artery. Retroportal
lymph nodes are resected according to the International
Study Group on Pancreatic Surgery guidelines [15]. The
hepatic duct is tunneled and transected.
After a 15–20 min break, a modified Blumgart
pancreatojejunostomy is performed (preferably using 3D
laparoscopy) using four 3/0 V-loc barbed sutures
(Covidien, New Haven, CT, USA), a 10 cm 6–8 Fr internal
pancreatic stent, and four to six duct-to-mucosa sutures
(Vicryl (Ethicon Inc., Cincinnati, OH, USA) or Novosyn
(B. Braun, Melsungen, Germany). In this way, the jejunal
wall is folded around the pancreatic stump. Approxi-
mately 5–7 cm distally, on the same jejunal loop, an end-
to-side hepaticojejunostomy is performed, either using 10
to 15 12 cm long Vicryl 4/0 interrupted sutures or either
two 4/0 V-loc barbed (Covidien, New Haven, CT, USA) or
polydioxanone (Ethicon Inc., Cincinnati, OH, USA) run-
ning sutures. Through a right subcostal stab incision, a 27
Fr surgical drain is placed through Winslow up to the su-
perior border of the pancreaticojejunostomy. Cholecystec-
tomy is now completed. An antecolic 4–5 cm end-to-side
gastrojejunostomy is performed using an endostapler, and
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closed using a V-loc barbed 3/0 suture (Covidien, New
Haven, CT, USA). In the case of a pylorus-preserving
pancreatoduodenectomy, an end-to-side duodenojejunost-
omy is performed using running V-loc barbed 3/0 sutures
(Covidien, New Haven, CT, USA). The specimen is
extracted through a Pfannenstiel incision, which is subse-
quently closed in layers. A second surgical drain is placed
from the right, at the inferior border of the pancreaticoje-
junostomy with the tip under the gastrojejunostomy.
Alternatively, this second drain may be placed from the
left. After hemostatic control, trocars are removed and all
12 mm fascia openings and the skin are closed. Optionally,
preperitoneal continuous wound catheters are placed [16].
For robot-assisted pancreatoduodenectomy, the
Pittsburgh approach is followed [17].
Control: open pancreatoduodenectomy
Patients undergo multimodal pain therapy with either an
epidural catheter or preperitoneal wound catheters with
patient controlled analgesia [16]. Subcostal laparotomy is
performed. The steps taken are essentially similar to
MIPD but the variation in technique is expected to be lar-
ger. Since outcomes of open pancreatoduodenectomy in
the Netherlands are good, the surgical technique in the
control arm reflects their usual practice; also, the anasto-
moses will be performed according to local protocol.
Fig. 1 LEOPARD-2 trial flow diagram according to SPIRIT [36]. EQ-5D-5 L, Euro-QoL five health dimensions questionnaire; HA, hepatic artery; IC,
informed consent; PV, portal vein; QLQ-C30, Quality of life questionnaire including 30 questions; SMA, superior mesenteric artery; SMV, superior
mesenteric vein
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Procedure variations according to the surgeon’s preference
are allowed, but must be recorded in the case record form.
A surgical drain can be placed.
Conversion from MIPD to open pancreatoduodenectomy
Conversion is defined as any MIPD (laparoscopic or
robot-assisted) in which a skin incision is used for reasons
other than trocar placement or specimen extraction. An
unplanned open reconstruction in a patient randomized
for MIPD in whom the procedure was started minimally
invasively (i.e. procedure with laparoscopic resection and
open reconstruction) will be reported as conversion.
Patients allocated to MIPD who undergo intraoperative
conversion to open pancreatoduodenectomy will still be
analyzed in the MIPD group according to intention-to-
treat principles. Reasons for conversion are registered and
categorized in urgent and non-urgent conversions [18].
Patient blinding
Patients will be blinded until functional recovery has
been reached or at least up to day 5 postoperatively
using a large (40 cm × 40 cm) abdominal dressing, which
is fixated on the abdomen at the end of the surgical
procedure. The quality of blinding is assessed by asking
patients whether they think the operation was performed
minimally invasive or via an open approach on day 3
and just before removing the abdominal dressing (i.e.
when functional recovery has been reached, or on day
5). If earlier inspection is required, attempts are made to
maintain patient blinding unless there is a medical
reason to remove the dressing (e.g. wound infection).
Previous trials in the Netherlands have found this
approach feasible [14, 19, 20]. A complete double-
blinding, including blinding of medical and nursing ward
staff, is not considered feasible.
General treatment regimen
Postoperative care is similar in both arms per center and
based on the enhanced recovery after surgery (ERAS®)
principle, which includes pain control, early mobilization,
and expansion of oral intake, as desired by the patient.
Enhanced recovery is standard practice in participating
centers. When patients are functionally recovered, they are
essentially medically ready to be discharged. Discharge will
however take place after shared decision making between
the patient and the local treating team and may be delayed
by arrangement of home care (e.g. for drain management).
Primary outcome measure
The primary outcome measure is time to functional
recovery (days), which will be daily assessed by the
nurses and ward physicians, and cross-checked by the
trial coordinators. Functional recovery is reached when
all of the following criteria are met [14]:
 Adequate pain control with oral analgesia only
 Restoration of mobility to an independent level (or
to preoperative level if previously impaired)
 Ability to maintain sufficient caloric intake
(minimum of 50% required calories)
 Absence of intravenous fluid administration
 No signs of active abdominal infection (In the case
of suspected or known abdominal infection this item
is met when the patient has no fever, and serum C-
reactive protein concentration is decreasing and
below 150 mg/L.)
Secondary outcome measures
The most important secondary outcome measure is the
overall rate of Clavien–Dindo III or higher complications.
Other secondary outcome measures include total proced-
ure time, operative time (first incision to skin closure),
intraoperative blood loss, conversion, complications (pan-
creatic fistula, delayed gastric emptying, chyle leakage,
postoperative bleeding, bile leakage, gastro- or duodenoje-
junostomy leakage, wound infection), re-intervention
(radiologic, endoscopic, or surgical), hospitalization
parameters (intensive care unit admission, readmission,
length of hospital stay, total of hospitalized days during
follow-up), adjuvant chemotherapy in patients with cancer,
mortality, and pathology outcomes (resected specimen
size, tumor size, histopathological diagnosis, resection
margins (in patients with cancer), lymph node retrieval,
tumor positive lymph node retrieval (in patients with
cancer), perineural and lymphovascular tumor invasion
(in patients with cancer), quality of life (EQ-5D-5 L and
QLQ-C30 questionnaires), survival, and costs.
Data collection and follow-up
Baseline characteristics will be collected before
randomization using standardized case record forms; this
comprises age (years), sex, performance status (Karnofsky
score), WHO physical status, American Society of
Anesthesiologists physical status, body mass index (kg/m2),
Malnutrition Universal Screening Tool score, medical
history, symptoms and duration of symptoms, conclusion
preoperative imaging, tumor size on imaging, TNM (tumor,
node, metastasis) stage on imaging, pancreatic duct
diameter on imaging (measured at the level of the portal
vein), tumor involvement of other organs, preoperative
expected diagnosis, preoperative biliary drainage, and use
of somatostatin analogs. Operative characteristics include
pancreatic texture (soft versus firm), pancreatic duct
diameter (mm), and type of anastomoses. Primary and
secondary outcome measures will be collected after
randomization up to 3 months postoperatively using
standardized case record forms by the local treating
physicians or the study coordinators. The case record
forms and the database will be cross-checked with source
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data by the study coordinators. Patients will be asked to
complete validated questionnaires on postoperative days 2,
4, and 6 (EQ-5D-5 L) and at 2 weeks, 4 weeks, and
12 weeks postoperatively (EQ-5D-5 L and QLQ-C30).
Please see Fig. 1. Long-term follow-up results of the
LEOPARD-2 trial (including complications and quality of
life) will be published separately.
Definitions
The pancreatic and periampullary region is defined as the
pylorus, the duodenum, the pancreatic head, and the distal
bile duct. Complications are classified using the Clavien–
Dindo score [21]. Major complications are defined as Cla-
vien–Dindo score III or higher. Pancreatic fistula [22, 23],
chyle leakage [24], delayed gastric emptying [25], and
postpancreatectomy hemorrhage [26] are classified using
the International Study Group on Pancreatic Surgery defi-
nitions. Bile leak is scored using the International Study
Group on Liver Surgery definition [27]. Surgical site infec-
tion is classified according to the Centers for Disease
Control and Prevention definition [28]. In the case of
malignancy, resection margins, including transectional
and circumferential margins, are classified as R0 (distance
margin to tumor > 1 mm), R1 (distance margin to tumor ≤
1 mm) and R2 (macroscopically tumor positive margin)
[29]. The TNM stage will be classified according to the
American Joint Committee on Cancer classification, 7th
and 8th editions.
Quality and safety
All participating surgeons have at least 5 years of experi-
ence in open pancreatoduodenectomy. Surgeons who
have completed LAELAPS training in minimally invasive
distal pancreatectomy and LAELAPS-2 training in
MIPD, and who have performed at least 20 MIPDs can
participate in the LEOPARD-2 trial. For robot-assisted
pancreatoduodenectomies, surgeons will have completed
the LAELAPS-3 training program, consisting of the da
Vinci® training course, video training, bio tissue training,
and proctoring on-site according to the Pittsburgh ap-
proach. Surgeons are considered to have passed the
learning curve for safety parameters associated with
MIPD after performing 20 MIPDs (excluding procedures
with open reconstruction), as confirmed by a recent
worldwide survey [5]. To obtain a high quality of surgi-
cal care in the LEOPARD-2 trial, the protocol committee
developed six quality criteria that must be met to allow
participation in the trial. All participating surgeons will
have to meet the following criteria:
 Performed ≥ 50 advanced minimally invasive
gastrointestinal procedures (Advanced laparoscopic
gastrointestinal procedure: defined arbitrarily as any
laparoscopic gastrointestinal procedure beyond
diagnostic laparoscopy, cholecystectomy, and
appendectomy.)
 Completed LAELAPS training in minimally invasive
distal pancreatectomy
 Completed LAELAPS-2 training in MIPD
 Performed ≥ 50 pancreatoduodenectomies (either
MIPD or open pancreatoduodenectomy)
 Performed ≥ 20 MIPDs
 Employed in a center in which ≥ 10 MIPDs and ≥ 20
pancreatoduodenectomies (minimally invasive and
open) are performed annually (This cut-off for
MIPD is based on a large registry study from the
USA [30]. The cut-off for all pancreatoduodenec-
tomies is similar to the current guideline of the
Dutch surgical society.)
Surgical videos of procedures performed within the
MIPD group will be collected. Technical quality will be
assessed at the end of the study by an independent expert.
All (serious) adverse events up to 3 months postoperatively
will be recorded. Only serious adverse events will be re-
ported through a web portal to the central committee on
research involving human subjects (in Dutch: Centrale
Commissie Mensgebonden Onderzoek) and the accredited
institutional review board (www.toetsingonline.nl). This in-
cludes all serious adverse events that necessitate intensive
care unit admission, surgical intervention, or readmission,
or result in (all-cause) mortality. The remaining events are
recorded in an annual overview list. An independent data
safety monitoring board will discuss safety parameters after
25, 40 (i.e. at completion of phase 2), 80, and 110 inclu-
sions. The data safety monitoring board exists of an inde-
pendent statistician or epidemiologist, an independent
gastroenterologist, and an independent surgeon (who will
chair the board). The advice of the data safety monitoring
board meeting will be shared with the steering committee
and the sponsor of the trial.
Go/no-go decision
After completion of phase 2, the results will be discussed
in a meeting of the data safety monitoring board and the
protocol committee. This moment is considered the “go/
no-go” decision. Phase 3 of the LEOPARD-2 trial will only
follow when the data safety monitoring board and the
protocol committee have no concerns on patient safety.
The conclusions of the data safety monitoring board and
the protocol committee will be sent to the medical ethics
review committee.
Statistical aspects
Sample size calculation
The LEOPARD-2 trial is designed as a phase 2/3 superior-
ity trial, hypothesizing that the postoperative time to func-
tional recovery is shorter after minimally invasive than
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open pancreatoduodenectomy. Based on a systematic re-
view and meta-analysis [4], a time to functional recovery of
14 days in the control group (open pancreatoduodenect-
omy) versus 11 days in the intervention group (MIPD) is
expected, with a standard deviation of 5 days. Significance
level (α) is set at 0.05 and power (1 − β) at 80%. Including
10% of cross-over from MIPD to open pancreatoduode-
nectomy, 2% loss to follow-up rate (based on previous sur-
gical trials in the Netherlands), 10% of patients with
metastasized disease (included, but oversampled to allow
sufficiently powered per-protocol analyses), and after divid-
ing by the asymptotic relative efficiency parameter of the
Mann–Whitney U test (0.955) because of expected non-
normally distributed data, 68 patients will be randomized
in each group. Thus, in total 136 patients will be random-
ized within the LEOPARD-2 trial.
Statistical analysis
Primary and secondary outcomes will be cross-checked
with data from primary sources and a blinded adjudication
committee (blinded for treatment allocation) will check
them against the definitions, which were established before
the start of this trial. Categorical variables will be compared
using the chi-square or Fisher’s exact test as appropriate,
and values will be expressed as proportions with corre-
sponding risk ratios and 95% confidence intervals. The
distribution of continuous variables will be determined
using visual inspection and the Kolmogorov–Smirnov test.
For comparison of normally distributed continuous vari-
ables the independent-samples t-test will be used and
values will be expressed as means with standard deviations.
Continuous non-normally distributed variables will be
compared using the Mann–Whitney U test and values will
be expressed as medians with interquartile ranges.
The primary endpoint is a time-to-event endpoint.
However, considering that (a) the duration of recovery will
most probably be censored in only 4% of patients at a
maximum and that (b) taking the full length of the post-
operative observation period as a proxy estimate for the
time to recovery in these outlying patients will hardly
affect the comparison of the study groups because of the
non-parametric testing strategy with the Mann–Whitney
U test and, finally, that (c) a power of 80% for a Kaplan–
Meier analysis as its best alternative can only be achieved
at the cost of a much higher and infeasible patient inclu-
sion rate, we will analyze the data as if no censoring takes
place. Additionally, the percentage of patients per study
arm who do not recover during the observation period
will be reported as a secondary outcome measure.
A difference with a two-tailed P-value < 0.05 will be
considered statistically significant. A multivariable linear
regression model will be used to assess potential differ-
ences in primary outcome between groups in the pres-
ence of potentially confounding factors. Linear mixed
modeling will be applied to estimate differences between
groups in successive EQ-5D-5 L and QLQ-C30 assess-
ments over time. For exploratory purposes, a secondary
analysis will be performed, comparing outcomes for
patients with pancreatic ductal adenocarcinoma versus
other disease, comparing completed minimally invasive
(i.e. no conversion) versus open pancreatoduodenectomy
and comparing time to functional recovery between
minimally invasive and open pancreatoduodenectomy in
complicated (Clavien–Dindo grade III or higher compli-
cation) and uncomplicated cases and for the impact of
robot-assisted versus laparoscopic pancreatoduodenect-
omy. A non-inferiority analysis will be performed for
Clavien–Dindo grade III or higher complications. The
study has an 80% power (α = 0.05) to confirm non-
inferiority of minimally invasive versus open pancreato-
duodenectomy, when 15% fewer patients experience a
clinically relevant complication in the intervention group
than the control group (non-inferiority margin set at
8%). In the intervention group, robot-assisted proce-
dures may be performed. The amount of robot-assisted
procedures is expected to be less than 20%; these will be
analyzed separately during cost-analysis.
Premature termination of the study
After the start of LEOPARD-2 phase 3, no interim analysis
will be performed, since this is the first multicenter trial
on this topic and any outcome would add to the existing
knowledge and be relevant for clinicians worldwide. Also,
no stopping rule for superiority will be used since the
number of expected events is too small. An independent,
unblinded data safety monitoring board will analyze safety
end points and may advise the trial steering committee to
adjust or stop the study, or to perform a full interim
analysis.
Dissemination policy
The results of the LEOPARD-2 trial will be submitted to
a peer-reviewed journal regardless of the study outcome.
Authorship will be based on international guidelines.
Participants who do not fulfill the authorship criteria will
be listed as “collaborator”.
Discussion
The LEOPARD-2 trial is a multicenter randomized con-
trolled phase 2/3 trial designed to assess whether MIPD is
associated with a shorter time to functional recovery than
open pancreatoduodenectomy. LEOPARD-2 follows the
LEOPARD trial on minimally invasive versus open distal
pancreatectomy and the Longitudinal Assessment and
Realization of Minimally Invasive Distal Pancreatectomy
in the Netherlands training programs (LAELAPS-1, −2
and −3) in minimally invasive distal pancreatectomy, lap-
aroscopic, and robot-assisted pancreatoduodenectomy
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[11, 12]. These programs were initiated by the DPCG, a
national collaboration of surgeons, gastroenterologists,
medical oncologists, pathologists, (interventional) radiolo-
gists, dietitians, and nurses.
All randomized controlled trials on new surgical
techniques face a dilemma over when to start including
patients. During the design phase of the LEOPARD-2
trial, the timing of the start of the trial in relation to the
learning curve was discussed at several meetings. Previ-
ous surgical trials on minimally invasive surgery have
been criticized for their timing, because of either starting
too early or too late. For instance, the multicenter,
randomized controlled MANCHET trial on minimally
invasive fundoplication in gastro-esophageal reflux
disease was criticized for starting too early (i.e. before
completion of the learning curve) with consequently in-
ferior results for the minimally invasive approach [31,
32]. This was confirmed by a follow-up study (i.e. after
the learning curve) by the same group, which found su-
perior outcomes for minimally invasive fundoplication.
Recently, the ORANGE trial on minimally invasive liver
surgery was stopped early because of slow accrual owing
to strong patient and surgeon preference for the minim-
ally invasive approach [19]. One could conclude that this
trial was initiated too late, in a phase when both patients
and surgeons felt the minimally invasive approach was
shown to be superior, and the essential period of per-
ceived surgical equipoise had already been passed.
The DPCG initiated a structured training program for
minimally invasive pancreatic surgery in the Netherlands.
After training in minimally invasive distal pancreatectomy
(LAELAPS-1), outcomes were superior as compared with
the period prior to training, including 8% conversion rate
and 0% mortality in 130 minimally invasive procedures.
Consequently, the same teams of surgeons were trained in
laparoscopic pancreatoduodenectomy (LAELAPS-2).
Again, outcomes were sufficient, including 11% conver-
sion and 4% complication-related mortality in the first 114
procedures from four centers who completed ≥ 20 MIPDs
[12]. Next, the length of the learning curve was discussed,
taking the argument on timing (not too early, not too late)
into account. Based on the results for the first 114 proce-
dures and a previous report, a minimum of 20 total min-
imally invasive procedures was decided to be the cut-off
to participate in the LEOPARD-2 trial [33].
This cut-off of 20 procedures was also reported in an
international survey among 435 pancreatic surgeons [5].
Possibly, better outcomes could be obtained with higher
cut-offs, such as 80 procedures as reported in a study for
operative time, but not for conversion or mortality, where
20 procedures seemed to suffice [34]. However, as this
study does not focus on operative time as the primary
endpoint measure and such a high cut-off might lead to
the danger of performing the trial too late, leading to
passing the critical period of equipoise and both the pa-
tient’s and doctor’s preference shifting to some extent,
postponing the trial would be fatal for its execution. Fur-
thermore, it should be realized that it will take 4 to 8 years
for most centers to perform 80 procedures minimally in-
vasively. It would seem unethical if so many patients were
to be exposed to a potentially increased surgical risk dur-
ing such a long learning period. In other words, the cut-
off of 20 procedures was also chosen for pragmatic rea-
sons, including high external validity (i.e. reflecting clinical
practice in most centers), rather than for the highest likeli-
hood of positive results (i.e. superior outcomes for MIPD).
Another point of discussion is the primary endpoint.
As in the LEOPARD-1 [14] and ORANGE trials [19, 20],
postoperative time to functional recovery was chosen as
the most objective parameter for postoperative recovery.
Length of hospital stay was considered less objective, as
it is also related to patient preference, home care facil-
ities, and doctor preferences. An alternative endpoint
measure, overall or clinically relevant complications, has
mainly been reported in retrospective studies and a sig-
nificant difference between minimally invasive and open
pancreatoduodenectomy has not been confirmed by
case-matched studies or meta-analysis [3, 4]. Both com-
plications and length of hospital stay are, however,
assessed in the LEOPARD-2 trial and will be reported in
the final publication.
Because of the standardized reporting of the LAELAPS-
1 and −2 training programs, the LEOPARD-1 and −2 trial
registration, the LEOPARD-1 and −2 study protocols and
final publication of results, the internal validity can be well
interpreted. The LEOPARD-2 trial includes all adult
patients undergoing elective pancreatoduodenectomy for
nearly all indications. Additionally, surgical procedures
will be performed in both academic hospitals and large
teaching hospitals by surgeons who have all completed the
LAELAPS-1 and −2 training programs. This should be
taking into account when assessing the external validity of
LEOPARD-2. Our group strongly recommends this
approach of specific procedure-based training before start-
ing MIPD, given the obvious complexity of the procedure
with the required surgical skills.
Blinding of patients in surgical trials has long been
deemed impossible. However, several randomized
controlled surgical trials have shown that patient blinding
is feasible in case of a dedicated protocol committee and
trial coordination [14, 19, 20]. Multiple publications in
high-impact journals have emphasized the importance of
blinding in randomized studies, as in surgical studies
results are also likely to be influenced by the patient’s
expectation (i.e. the Hawthorne effect) [35]. As in the
LEOPARD trial, we attempt to improve study quality as
much as possible, and therefore decided to add patient
blinding. In this way, we minimize the effect of patient’s
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expectation on the primary study outcome measure, time
to functional recovery, an endpoint measure that is obvi-
ously influenced by psychological factors.
In conclusion, the LEOPARD-2 trial is a multicenter ran-
domized controlled phase 2/3, superiority trial investigat-
ing safety and time to functional recovery of MIPD and
open pancreatoduodenectomy performed by surgeons who
have performed ≥ 20 MIPDs within a dedicated training
program. This trial aims to provide level one evidence on
the added value of the minimally invasive approach in daily
practice within high-volume (>20 pancreatoduodenec-
tomies annually) centers, just after 20 procedures have
been performed. When this hypothesis is confirmed, it will
enhance the worldwide implementation of MIPD, and con-
sequently improve overall patient outcome.
Trial status
The first patient was randomized on 2 March 2016.
LEOPARD-2 phase 2 has been completed and we contin-
ued with LEOPARD-2 phase 3. At the time of protocol
submission (September 2017), four centers were actively
recruiting patients for the trial, two centers were about to
start recruiting, and 101 of 136 patients (74%) had been
randomized. Inclusion is according to schedule.
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